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Background: Empiric therapy of inpatient skin and soft tissue infections (SSTIs) generally require methicillin
resistant Staphylococcus aureus (MRSA) coverage. Limited data are available to directly compare the effect of initial
antibiotic choice on treatment outcomes and length of stay (LOS).
Objective: To assess potential differences in length of hospital stay when inpatients with complex skin and soft
tissue infections (SSTIs) were initially treated with either vancomycin, linezolid, or daptomycin.
Methods: A retrospective review of 219 patients diagnosed with inpatient SSTI who received linezolid, vancomycin,
or daptomycin for >48 hours was performed. Data collected included demographics, comorbidities, microbiologic/
laboratory data, additional management (surgical, non-study antibiotics), hospital LOS, treatment outcome and
morbidity/mortality.
Results: The three groups evaluated were linezolid (n = 45), vancomycin (n = 90) daptomycin (n = 84). There was no
difference between the three groups with respect to gender, age, comorbidities, leukocytosis, fever, antibiotics prior
to admission, site of infection culture results and surgical intervention. One death was recorded, not associated with
diagnosis of SSTI. No significant difference in LOS was found (P = 0.525) between the 3 groups. The mean LOS in
entire cohort was 4.5 days (SD ± 2.5); thirty patients had prolonged LOS for non-SSTI reasons; reanalyzing the data
without these 30 patients did not produce any difference in the mean LOS between the 3 groups. Switching
vancomycin just prior to discharge to facilitate outpatient therapy was common but did not impact LOS.
Conclusions: No difference was detected in hospital length of stay with respect to the initial choice of antibiotic
(linezolid, vancomycin, or daptomycin) for SSTI. The three antibiotic regimens were equally effective in treating
SSTIs as judged by LOS, irrespective of age, gender, comorbidities or baseline severity of SSTI. Given the large
standard deviation in LOS, this result should be confirmed by larger studies.
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Skin and soft tissue infections (SSTIs) account for a
large proportion of hospitalizations. In 2004, approxi-
mately 870,000 U.S. hospital admissions were due to
SSTIs, an increase of 29% over 2000 data (Edelsbert
et al. 2009). Though multiple studies have found vary-
ing average inpatient stays and costs for SSTIs, a re-
cent analysis found an average stay of 6.1 days and
cost ~6830 United States dollars (USD) per episode
(Menzin et al. 2010).
The most common organisms involved in SSTIs are
Staphylococcus aureus and B-haemolytic streptococci
(Rajan 2012). The initial treatment regimen is based on
clinical presentation, microbiologic data, hospital anti-
biogram, physician’s discretion and the pharmacy for-
mulary. Given growing antibiotic resistance, empiric
antimicrobial therapies for severe SSTIs must now have
MRSA activity, as about half of S. aureus infections are
methicillin resistant (Menzin et al. 2010; Rajan 2012).
Currently, the leading options for empiric inpatient
coverage for SSTIs are linezolid, vancomycin, and dap-
tomycin (Bounthavong et al. 2011). Ceftaroline, telavan-
cin, and tigecycline are newer, but less used, options in
this category (van Hal and Paterson 2011).
Daptomycin has superior in vitro bactericidal activ-
ity against MRSA when compared with vancomycin
and linezolid (Maraconescu et al. 2012). Multiple ana-
lyses have compared vancomycin (the incumbent
“gold standard”) to linezolid and daptomycin. Though
“suggestions” of superiority for daptomycin and/or li-
nezolid have been found (van Hal and Paterson 2011;
Bounthavong and Hsu 2012; Logman et al. 2010;
Davis et al. 2007), the actual value with respect to
hospital LOS from changing from initial therapy with
vancomycin, a time tested and inexpensive antibiotic,
to one of the more expensive newer agents as initial
therapy for inpatient SSTIs have not been convin-
cingly demonstrated. As part of a cost benefit analysis
at our medical center, we conducted a retrospective
study to evaluate the impact of initial inpatient antibiotic
choice (daptomycin, linezolid, or vancomycin) on SSTI
length of hospital stay.Methods
A retrospective cohort review was performed on Orlando
Health inpatients that were diagnosed with a skin or soft
tissue infection and received one of the three study antibi-
otics (daptomycin, linezolid, or vancomycin) between
January 2009 and September 2010. Charts were selected
by ICD-9 codes (680.0 – 686.9) and comprehensively
reviewed. One dose of a non-study antibiotic was permit-
ted prior to initiation of therapy with vancomycin, linezo-
lid or daptomycin.Inclusion criteria
Patients between the ages of 18–85 with an acute SSTI,
defined as three or more of the following: warmth, ery-
thema, swelling, pain, tenderness, lymph node swelling/
tenderness, drainage/discharge, or induration, for less
than two weeks. Patients were also included if they had
an abscess requiring incision and drainage at bedside or
in the operating room. Initial antibiotic treatment was
daptomycin, linezolid (intravenous or oral), or vanco-
mycin and continued for at least 48 hours. The choice of
initial antibiotic was entirely dependent on the attending
physician’s preference.
Exclusion criteria
Patients were excluded if they had osteomyelitis (sus-
pected or proven), decubitus ulcer, necrotizing fasciitis,
myositis, gas gangrene, a Gram positive isolate proven
resistant to one or more study antibiotics, Gram nega-
tive infection, or the presence of concomitant infection
upon admission (i.e. pneumonia, UTI).
Data collection, definitions, statistics
Hospital length of stay was evaluated in relation to the
specific antimicrobial regimen chosen on admission.
Length of stay was calculated based on nights spent in
the hospital. A prolonged stay occurred when patients
were kept in hospital beyond the requisite stay for SSTI
treatment for unrelated medical or social problems.
Additional data collected included demographics (age,
gender), clinical presentation (collected from physician’s
progress notes, including antibiotics prior to admission,
anatomical site of infection, vital signs, duration of symp-
toms), co-morbidities (HIV status, diabetes mellitus (DM),
peripheral vascular disease (PVD), end stage renal disease
(ESRD), immunosuppressive therapy, malignancy), so-
cial history (tobacco use), and laboratory/radiological
data (white blood cell count, microbiological data, cre-
atinine, imaging). Treatment data collected included
surgical/bedside interventions performed, intensive care
unit admission, additional non-study antibiotics admin-
istered, and whether a switch in therapy occurred.
Switching of antibiotic was defined as a switch from
study antibiotic to a different study antibiotic or another
non-study antibiotic during the hospitalization. Switch-
ing of antibiotics was classified into one of the following
categories:
1. Transition to outpatient therapy: (changing to oral
or simplified once daily intravenous therapy).
2. Treatment failure. No clinical improvement
after ≥48 hours; switched to a different antibiotic
based on physician’s judgment.
3. De-escalation to a B-lactam antibiotic after
organism identification and susceptibility available










Figure 2 Patients with prolonged LOS for non-SSTI reasons
eliminated (N = 189).
Table 1 Clinical and microbiologic features of SSTIs
Daptomycin Linezolid Vancomycin P value
Antibiotics prior
to admission
29 (34) 11 (24) 20 (22) 0.16
Adenopathy 6 (7) 0 (0) 9 (10) 0.09
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Group A streptococci).
4. Allergy or adverse reaction.
5. Therapeutic preference of the attending physician.
Descriptive statistics for all data were collected and
stored using Microsoft Excel software. Statistical tests
were performed using SPSS software with a p value < 0.05
used to define statistical significance. Nominal data were
compared by using the Pearson X2 test. Age and length of
stay measures were analyzed using an ANOVA.
This research was approved through the Institutional
Review Board (IRB) at Orlando Health.
Results
Four hundred and seventy two charts were reviewed; a
total of 219 patients met the inclusion criteria (daptomy-
cin n = 84, linezolid n = 45, and vancomycin n = 90). No
difference in hospital length of stay was observed re-
gardless of initial antibiotic choice for patients admitted
to the hospital with skin and soft tissue infection
(p = 0.53) (Figure 1). The mean LOS in entire cohort
was 4.5 days (SD ± 2.5). Thirty patients had a prolonged
hospital length of stay beyond what was required for
treatment of their SSTI; the data with these patients
excluded also showed no difference in LOS: (n = 189,
p = 0.49) (Figure 2).
The mean age in the daptomycin, linezolid and vanco-
mycin groups was 49, 48, and 52 years (SD+/− 2.5), re-
spectively. There was no difference in gender (p = 0.64),
history of intravenous drug (p = 0.90) or tobacco use
(p = 0.26). The clinical presentation was not significantly
different between the three antibiotic groups when eval-
uated by preadmission antibiotics, site of infection cul-
ture results, adenopathy, fever, leukocytosis, drainable
foci, radiological evidence of infection, or requirement
for surgical intervention (Table 1). Furthermore, except
for end stage renal failure which was over represented
in the daptomycin group (p = 0.038), there was no
difference between observed co-morbidities including4.76 ± 2.63
4.24 ± 2.14 
4.48 ± 2.28







Figure 1 Hospital length of stay (LOS) (N = 219).diabetes, heart failure, immunosuppressive drugs, HIV,
peripheral vascular disease, history of malignancy, his-
tory of transplant, or previous known colonization with
MRSA (Table 2). Vancomycin levels were collected in
44 cases (49%), with trough levels >/= 10 mg/L in 87%
cases (n = 38).
There was a significant difference in switching of anti-
biotics during treatment. The vancomycin group had the
highest percentage of switching (55%), followed by dap-
tomycin (19%), and linezolid (11%) (p < 0.05). The most
common reason for switching antibiotics in all groups
was a transition to outpatient therapy; 88% of vanco-
mycin changes were to either daptomycin, so as to facili-
tate once daily outpatient intravenous antibiotic therapy,
or a transition to oral treatment. The vancomycin pa-
tients changed to daptomycin almost invariably occurred
on the last hospital day and had no influence on LOS.
Only one patient in any group (daptomycin) was changedFever 14 (16) 7 (15) 20 (22) 0.53
Leukocytosis 53 (63) 20 (44) 46 (51) 0.09
Drainable Foci 34 (40) 16 (35) 38 (42) 0.75
Coadministration
non-study antibiotic
64 (76) 32 (71) 76 (84) 0.16
Radiological evidence
of collection/abscess
10 (11) 2 (4) 12 (13) 0.27
Wound +MRSA 26 (31) 13 (29) 28 (31)
Wound +MSSA 7 (8) 7 (16) 7 (8)
Positive blood
cultures*
2 (2) 0 4 (4)
*All positive blood cultures were MRSA.
n (%).
Pearson X2 test analysis.
Table 2 Comorbidities of SSTI patients
Daptomycin Linezolid Vancomycin P value
Diabetes 24(28) 9(20) 23(25) 0.56
Heart failure 1(1) 3(6) 3(3) 0.24
ESRD 7(8) 0(0) 2(2) 0.03
Immunosuppressive
therapy
4(4) 1(2) 5(5) 0.67
HIV 1(1) 3(6) 6(6) 0.16
Peripheral vascular
disease
6(7) 3(6) 4(4) 0.73
History malignancy 5(6) 1(2) 11(12) 0.09
History transplant 1(1) 1(2) 3(3) 0.63
Colonized MRSA 9(10) 5(11) 9(10) 0.97
n (%).
Pearson X2 test analysis.
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cluded or switched because of Gram positive resistance.
One death was recorded, not associated with the diag-
nosis of SSTI.
Discussion
This retrospective “real-world” study found no signifi-
cant differences in length of stay between the three most
commonly used empiric inpatient anti-MRSA antibiotics
for skin and soft tissue infections requiring inpatient
care. Previous in vitro work supports daptomycin as the
superior agent (Maraconescu et al. 2012). Multiple clin-
ical studies, analyses and reviews, have suggested a
possible advantage for linezolid (Menzin et al. 2010;
Bounthavong et al. 2011; van Hal and Paterson 2011;
Bounthavong and Hsu 2012; Logman et al. 2010; Itani
et al. 2012; Barron et al. 2012; Watkins et al. 2012) or
daptomycin (Itani et al. 2010; Quist et al. 2012; Falcone
et al. 2012; Bliziotis et al. 2010; Davis et al. 2007) as
compared to vancomycin in terms of time to clinical
cure, hospital length of stay, or both. Despite the evi-
dence favoring linezolid or daptomycin over vanco-
mycin, some authors have been unconvinced of the
clinical relevance of the purported superiority of the







De-escalation 3 1 4
Transition to outpatient 11 2 44
Presumed treatment failure 1 0 0
Allergy or adverse effect 0 1 1
Therapeutic preference 1 1 1focus on LOS as a single key parameter of efficacy as it
is closely tied to hospital cost and is more straightfor-
ward than assessment of clinical parameters such as
time of resolution of cellulitis, etc.
Vancomycin’s main advantages are its 50 year track
record and low cost, but its use requires careful moni-
toring to avoid nephrotoxicity (van Hal and Paterson
2011). Though overt resistance remains rare, some insti-
tutions have noted “MIC Creep,” a situation in which
vancomycin MICs ≥1.5 mg/l are found with increasing
frequency. Such isolates may be difficult to cure with
vancomycin, even at higher doses (Brink 2012). At our
institution, such isolates comprise <1.5% of all Staphylo-
coccus aureus isolates using the Vitek 2 methodology
(BioMerieux). Daptomycin is a remarkably easy drug to
use, but it may occasionally cause myopathy or serious
eosinophilic pneumonia (van Hal and Paterson 2011). A
larger concern is the increasing frequency of daptomy-
cin resistance (van Hal and Paterson 2011; van Hal
et al. 2011; Velazquez et al. 2013). Linezolid is the sim-
plest of the three antibiotics, given its high oral bio-
availability and simple intravenous to oral conversion,
but its use may be complicated by thrombocytopenia,
peripheral neuropathy and drug interactions with se-
lective serotonin inhibitors (Rajan 2012). Resistance to
linezolid remains rare, but may be increasing (van Hal
and Paterson 2011).
This retrospective study has limitations. The patients
were allocated into groups by the preferences of the at-
tending physicians, many of whom held strong views on
the relative superiority of one agent vs. the others. At-
tendings may have started “sicker” patients on the non-
vancomycin regimens, though we have no evidence this
occurred as the groups were comparable with respect to
demographics, admission WBC, fever and baseline co-
morbidities. Institutions with diminishing vancomycin
susceptibility may experience poorer outcomes with
vancomycin use. The study may have been underpow-
ered to detect differences; larger numbers might have
turned the trend in favor of linezolid into a statistically
significant finding.
Vancomycin remains a key antibiotic in the gram
positive armamentarium. We found no evidence for
any significant difference in length of stay for SSTI
between the three common initially used inpatient
agents, and are continuing to advise clinicians at our
medical center to start with vancomycin for compli-
cated inpatients SSTIs, (unless there were contraindi-
cations), both to limit cost and the risk of daptomycin
or linezolid resistance. How long vancomycin will re-
main the workhorse inpatient choice remains unclear,
and will likely depend on differential resistance among
these 3 agents, new drugs such as ceftaroline, and ex-
ternal economic factors.
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